ERBB2 and carcinoma: The comparable potency of chemically conjugated trastuzumab-DM1 and sortase-conjugated trastuzumab-maytansine ADCs in vitro was also confirmed by an in vivo xenograft mouse model, involving human HER-2-positive SKOV3 carcinoma cells.